

•



Aug 13, 2020

© Competitive enzyme-linked immunosorbent assay for investigating SpL binding to mammalian and avian immunoglobulins

Angel A Justiz-Vaillant¹

¹University of the West Indies St. Augustine

Angel Justiz-Vaillant

1 Works for me dx.doi.org/10.17504/protocols.io.bjqckmsw
University of the West Indies angel.vaillant@sta.uwi.edu

University of the West Indies St. Augustine

ABSTRACT

This ELISA was based on the theory that antibodies present in different samples would compete with human IgG for binding to SpL, resulting in inhibition of human IgG-SpL interactions [1].

Reference:

1. Justiz-Vaillant AA, Akpaka PE, McFarlane-Anderson N, Smikle MF. Comparison of techniques of detecting immunoglobulin-binding protein reactivity to immunoglobulin produced by different avian and mammalian species. *West Indian Med J.* 2013;62(1):12-20.

DOI

dx.doi.org/10.17504/protocols.io.bjqckmsw

PROTOCOL CITATION

Angel A Justiz-Vaillant 2020. Competitive enzyme-linked immunosorbent assay for investigating SpL binding to mammalian and avian immunoglobulins. **protocols.io** https://dx.doi.org/10.17504/protocols.io.bjqckmsw

LICENSE

This is an open access protocol distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

CREATED

Aug 13, 2020

LAST MODIFIED

Aug 13, 2020

PROTOCOL INTEGER ID

40420

- This ELISA is based on the theory that antibodies present in different samples would compete with human IgG for binding to SpL, resulting in inhibition of human IgG-SpL interactions.
- The samples tested are commercially prepared pooled sera from skunk, coyote, raccoon, duck, and also commercially prepared purified immunoglobulins from cat and chicken (SigmaAldrich Co, St Louis, Missouri).

Citation: Angel A Justiz-Vaillant (08/13/2020). Competitive enzyme-linked immunosorbent assay for investigating SpL binding to mammalian and avian immunoglobulins. https://dx.doi.org/10.17504/protocols.io.bjqckmsw

3	The microplate is coated with 50 μ l of commercial human IgG (1 μ g/well overnight at 4°C).
4	Serial doubling dilutions (1:4 to 1:1024) of 30 μ l of each sample are made in a separate microplate to which 30 μ l of the conjugate SpL-HRP diluted 1:1000 in non-fat milk is added.
5	The microplate is incubated for one hour at RT and then 50 μ l of each sample is transferred to the human IgG coated microplate and incubated for one hour.
6	The microplate is then washed four times with PBS-Tween 20 buffer (SigmaAldrich Co, St Louis, Missouri), and 50 μ l of the substrate OPD (3 mg/ml) is added to each well and incubated at RT for 15 minutes.
7	The reaction is stopped with 3M H2SO4 and the microplate is visually assessed and read at 492 nm.
8	The percentage of the binding inhibition (I%) of the SpL-human IgG interactions by different samples was calculated.